Form D · Pharmaceuticals

Endo, Inc.

Malvern, PA · CIK 0002008861

Offering snapshot reported May 6, 2024 · SEC filing

Reported sold: $171M
Investors reported: 404
Minimum accepted: $0
First sale: Mar 21, 2024

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$0 → $170,574,224
Reported investors55 → 404

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
May 6, 2024	Amendment	$170,574,224	$170,574,224vs Mar 21, 2024	404	SEC filing
Mar 21, 2024	Initial	$0	No comparison	55	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-508269

Source: Form D, filed May 6, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Patrick Barry	Executive
Mark Bradley	Director, Executive
Blaise Coleman	Director, Executive
Paul Efron	Director
Paul Herendeen	Director
Scott Hirsch	Director
Sophia Langlois	Director
Matthew Maletta	Executive
Brian Morrissey	Executive
Andy Pasternak	Director
Frank Raciti	Executive
Deanna Voss	Executive
Marc Yoskowitz	Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

1400 Atwater Drive
Malvern, PA, 19355